Zymeworks Inc.
CAFinancials
Valuation Metrics
Zymeworks Inc.'s Market Cap is $1.95B. At end of 2025 it was $1.98B. Ranked #2026 of 3,121 in US market (top 65%), #774 of 1,463 on NASDAQ (top 53%), #139 of 266 in Pharmaceuticals, Biotechnology & Life Sciences (top 52%) by Market Cap.
Investment Metrics(as of 2026-09-19)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $1.95B | US#2,026/3,121 Sec#139/266 |
| Revenue | $37M | US#2,792/3,121 Sec#157/266 |
| Net Income | $-150M | US—/3,121 Sec—/266 |
| Total Assets | $397M | US#2,844/3,121 Sec#187/266 |
| Net Assets | $80M | US#2,834/3,121 Sec#219/266 |
| Employees | 231 | US#2,471/3,121 Sec#125/266 |
| Value | ||
| P/B | 24.32x | US#2,830/3,121 Sec#225/266 |
| P/S | 52.65x | US#2,920/3,121 Sec#165/266 |
| FCF Yield | -6.15% | US—/3,121 Sec—/266 |
| Profitability | ||
| ROE | -186.63% | US#2,842/3,121 Sec#217/266 |
| ROA | -37.78% | US#2,937/3,121 Sec#183/266 |
| Op. Margin | -418.99% | US#2,801/3,121 Sec#152/266 |
| Revenue Growth | -69.78% | US#2,759/3,121 Sec#174/266 |
| Financial Health | ||
| Debt Ratio | 393.93% | US#2,266/3,121 Sec#221/266 |
| Total Debt | $269M | US#2,145/3,121 Sec#86/266 |
| FCF | $-120M | US#2,673/3,121 Sec#158/266 |
| Cash | $179M | US#1,822/3,121 Sec#123/266 |
| Current Ratio | 6.32x | US#384/3,121 Sec#122/266 |
| Performance | ||
| 1Y Return | 61.13% | US#338/3,121 Sec#82/266 |
| 1M Return | -2.35% | US#455/3,121 Sec#47/266 |
| From 52W High | -15.22% | US#921/3,121 Sec#64/266 |
| 1Y MDD | -23.63% | US#965/3,121 Sec#45/266 |
| Trading | ||
| Volume | 687,460 shares | US#1,990/3,121 Sec#209/266 |
| Trading Value | $18M | US#2,127/3,121 Sec#170/266 |
| Per Share | ||
| EPS | $-2.04 | US—/3,121 Sec—/266 |
| BPS | $1.09 | US#2,686/3,121 Sec#202/266 |
Company Info
Zymeworks Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to identifying, advancing, and bringing to market biological therapies aimed at combating cancer. Its pipeline features two primary experimental treatments: zanidatamab, a cutting-edge bispecific antibody currently undergoing Phase 1 and Phase 2 studies for various malignancies such as those affecting the biliary tract, gastroesophageal region (adenocarcinomas), breast, and colon; and ZW49, an antibody-drug conjugate targeting two sites on the human epidermal growth factor receptor 2 (HER2), which is in Phase 1 trials for advanced or spreading tumors that express HER2. Zymeworks maintains significant alliances with several pharmaceutical leaders, including Merck Sharp & Dohme Research Ltd., Eli Lilly and Company, Bristol-Myers Squibb company, GlaxoSmithKline Intellectual Property Development Ltd., Daiichi Sankyo Co., Ltd., Janssen Biotech, Inc., BeiGene, Ltd., and Exelixis, Inc. Furthermore, it engages in cooperative research and licensing agreements with LEO Pharma A/S, specifically for the exploration, advancement, and market introduction of bispecific antibodies, and with Iconic Therapeutics, Inc. Established in 2003, Zymeworks Inc. operates from its headquarters located in Vancouver, Canada.